Literature DB >> 33068913

Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide Assessment.

Larry Alphs1, Dong-Jing Fu2, David Williamson1, Ibrahim Turkoz3, Carol Jamieson4, Dennis Revicki5, Carla M Canuso3.   

Abstract

The psychometric properties of the Suicide Ideation and Behavior Assessment Tool (SIBAT) were evaluated in 130 participants with varying levels of suicidality. Inter- and intra-rater reliability were assessed for clinician-rated outcomes, including the revised Clinical Global Impressions (CGI) of severity of suicidality (CGI-SS-r). Concurrent validity of patient-reported modules with Patient-reported Outcomes Measurement Information System (PROMIS) depression scale and Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure (S-STS CMCM), and concordance between Columbia Classification Algorithm of Suicide Assessment (C-CASA) mappings for SIBAT, S-STS CMCM and Columbia-Suicide Severity Rating Scale (C-SSRS) were assessed. 52/130 participants (mean [SD] age: 38.3 [17.77] years) consented for multiple interviews (C-CASA mappings: n=52; rater-reliability: n=25/52). SIBAT demonstrated good intra-rater reliability (weighted-kappa range:0.64-0.76; CGI-SS-r, 0.75) and adequate inter-rater reliability (ICC range:0.68-0.82; CGI-SS-r, 0.81). There were strong correlations between PROMIS depression scores and SIBAT Module 5 ratings (Spearman correlations, r=0.64-0.74) and moderate correlations (r=0.29-0.72) between S-STS CMCM and SIBAT Modules 2, 3 and 5 ratings. Moderate agreement was noted between SIBAT C-CASA mappings and corresponding mappings from S-STS CMCM (weighted kappa: 0.54) and C-SSRS (weighted kappa: 0.56). Thus, the SIBAT provided valid assessment of suicidal ideation and behavior that could be reliably rated and adequately mapped to the C-CASA.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-CASA; rater-reliability; suicide behavior; suicide ideation

Year:  2020        PMID: 33068913     DOI: 10.1016/j.psychres.2020.113495

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

Review 1.  Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.

Authors:  Sina Nikayin; Gerard Sanacora
Journal:  CNS Drugs       Date:  2021-09-07       Impact factor: 5.749

2.  SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties.

Authors:  Larry Alphs; Dong-Jing Fu; David Williamson; Carol Jamieson; John Greist; Magdalena Harrington; Jean-Pierre Lindenmayer; Cheryl McCullumsmith; David V Sheehan; Richard C Shelton; Paul Wicks; Carla M Canuso
Journal:  Innov Clin Neurosci       Date:  2022 Apr-Jun

3.  Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray.

Authors:  Heather Rozjabek; Nan Li; Holger Hartmann; Dong Jing Fu; Carla Canuso; Carol Jamieson
Journal:  J Patient Rep Outcomes       Date:  2022-07-10

Review 4.  [Are psychedelics fast acting antidepressant agents?]

Authors:  Gerhard Gründer; Manuela Brand; Laura Kärtner; Dennis Scharf; Christian Schmitz; Moritz Spangemacher; Lea J Mertens
Journal:  Nervenarzt       Date:  2022-02-01       Impact factor: 1.214

5.  Correlation between suicidal ideation and emotional memory in adolescents with depressive disorder.

Authors:  Shuwen Hu; Daming Mo; Pengfei Guo; Hongyu Zheng; Xiaolu Jiang; Hui Zhong
Journal:  Sci Rep       Date:  2022-03-31       Impact factor: 4.379

Review 6.  A Southeast Asian expert consensus on the management of major depressive disorder with suicidal behavior in adults under 65 years of age.

Authors:  Kok Yoon Chee; Nalini Muhdi; Nor Hayati Ali; Nurmiati Amir; Carmina Bernardo; Lai Fong Chan; Roger Ho; Pichai Ittasakul; Patanon Kwansanit; Melissa Paulita Mariano; Yee Ming Mok; Duy Tam Tran; Thi Bich Huyen Trinh
Journal:  BMC Psychiatry       Date:  2022-07-21       Impact factor: 4.144

7.  Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).

Authors:  Dawn F Ionescu; Dong-Jing Fu; Xin Qiu; Rosanne Lane; Pilar Lim; Siegfried Kasper; David Hough; Wayne C Drevets; Husseini Manji; Carla M Canuso
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.